Stocks›Healthcare›HALO

HALO

HALOZYME THERAPEUTICS, INC.

NasdaqResearch view

Healthcare · Biological Products, (No Diagnostic Substances) · Large-cap · SEC EDGAR FY 2025-12-31

Price history

Chart: TradingView’s own feed · page prices: 1D EOD

🔒 Click to interact · scroll moves the page

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$12.1B

Enterprise Value$14.1B

Income$316.9M

Sales$1.4B

Book/sh$0.43

Cash/sh$1.20

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio3.66

Current Ratio4.66

Debt/Eq43.89

EPS (ttm)$2.56

EPS this Y-25.4%

EPS past 3/5Y21.1%

Sales past 3/5Y28.4%

EPS Y/Y TTM-25.4%

Sales Y/Y TTM37.6%

Shs Outstand113.50M

ROA12.5%

ROE649.2%

ROIC15.5%

Gross Margin—

Oper. Margin33.6%

Profit Margin22.7%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

$443.3M

2021

$660.1M

2022

$829.3M

2023

$1.0B

2024

$1.4B

2025

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$443.3M	$660.1M	$829.3M	$1.0B	$1.4B
Gross Profit	—	—	—	—	—
Operating Income	$275.9M	$267.5M	$337.6M	$551.5M	$469.0M
Net Income	$402.7M	$202.1M	$281.6M	$444.1M	$316.9M
Diluted EPS	$2.74	$1.44	$2.10	$3.43	$2.56
Operating Cash Flow	$299.4M	$240.1M	$388.6M	$479.1M	$651.6M
Free Cash Flow	$298.0M	$235.3M	$373.3M	$468.4M	$644.6M

Deep dive

Computed from the SEC EDGAR multi-year statements

Operating leverage — margins

GrossOperatingNet

FY25 cash-flow waterfall

Capital-light: capex is $7.0M against $651.6M operating cash

Follow the news. Track the move.

HALO story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Sep 16

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033

Halozyme said it intends to offer $1.05 billion of convertible senior notes due 2033, subject to market conditions and other factors. The proposed financing adds potential dilution and interest obligations, while the use of proceeds and final conversion terms will determine the setup for HALO.

Price history unavailable

PR Newswire · 7h ago

View both sides →

Follow the news. Track the move.